Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Foye

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
European Urology|April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate CancerWilliam S Chen, Rahul Aggarwal, Li Zhang, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
Nature Genetics|July 17, 2024
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancerShuang G Zhao, Matthew Bootsma, Stanley Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective StudyRahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, et al.
NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Nature Communications|September 15, 2022
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticityThomas C Westbrook, Xiangnan Guan, Eva Rodansky, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
European Urology|April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate CancerWilliam S Chen, Rahul Aggarwal, Li Zhang, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
Nature Genetics|July 17, 2024
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancerShuang G Zhao, Matthew Bootsma, Stanley Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective StudyRahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, et al.
NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Nature Communications|September 15, 2022
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticityThomas C Westbrook, Xiangnan Guan, Eva Rodansky, et al.
Pageof 4